FIELD: chemistry.
SUBSTANCE: invention relates to antibacterial compounds of formula I, where R1-R4, X, Y, Z are defined in the claim, which have a wide spectrum of bioactivity. In various embodiments, the compounds act by inhibiting type 1 bacterial signal peptidases, important proteins in bacteria. Also disclosed are pharmaceutical compositions and methods of treating bacterial infections using said compounds.
EFFECT: compounds of the invention are applicable for treating infections caused by gram-negative bacteria, and are particularly applicable in treating an infection associated with non-enzymatic bacteria.
69 cl, 7 tbl, 76 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MACROCYCLIC WIDE-RANGE ANTIBIOTICS | 2018 |
|
RU2779477C2 |
| INFLUENZA VIRUS REPLICATION INHIBITORS, METHODS OF APPLICATION AND USING | 2016 |
|
RU2737190C2 |
| THIENOPYRROL DERIVATIVES FOR APPLICATION FOR TARGETING PROTEINS, COMPOSITIONS WITH SAID DERIVATIVES, METHODS AND APPLICATIONS | 2017 |
|
RU2771166C2 |
| FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2679914C9 |
| SERINE/THREONINE KINASE INHIBITORS | 2013 |
|
RU2650501C2 |
| PYRAZOLE-BASED MAGL INHIBITORS | 2018 |
|
RU2789157C2 |
| PHARMACEUTICAL AGENT CONTAINING INHIBITOR OF SODIUM-DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2740008C2 |
| SUBSTITUTED HETEROCYCLIC SULPHONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | 2014 |
|
RU2675792C2 |
| SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2815814C1 |
| PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
